JP4535424B2 - 多発性骨髄腫の治療法 - Google Patents

多発性骨髄腫の治療法 Download PDF

Info

Publication number
JP4535424B2
JP4535424B2 JP2003510066A JP2003510066A JP4535424B2 JP 4535424 B2 JP4535424 B2 JP 4535424B2 JP 2003510066 A JP2003510066 A JP 2003510066A JP 2003510066 A JP2003510066 A JP 2003510066A JP 4535424 B2 JP4535424 B2 JP 4535424B2
Authority
JP
Japan
Prior art keywords
antibody
seq
region
kma
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003510066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504018A5 (enExample
JP2005504018A (ja
Inventor
ロバート リンズセイ レイソン
ロザンヌ ドロシー ダン
ブーン ワ アンドレ チュー
Original Assignee
イミューン システム セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューン システム セラピューティクス リミテッド filed Critical イミューン システム セラピューティクス リミテッド
Publication of JP2005504018A publication Critical patent/JP2005504018A/ja
Publication of JP2005504018A5 publication Critical patent/JP2005504018A5/ja
Application granted granted Critical
Publication of JP4535424B2 publication Critical patent/JP4535424B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003510066A 2001-07-06 2002-07-05 多発性骨髄腫の治療法 Expired - Lifetime JP4535424B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6179A AUPR617901A0 (en) 2001-07-06 2001-07-06 Method for treating multiple myeloma
PCT/AU2002/000896 WO2003004056A1 (en) 2001-07-06 2002-07-05 Method for treating multiple myeloma

Publications (3)

Publication Number Publication Date
JP2005504018A JP2005504018A (ja) 2005-02-10
JP2005504018A5 JP2005504018A5 (enExample) 2005-10-27
JP4535424B2 true JP4535424B2 (ja) 2010-09-01

Family

ID=3830143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510066A Expired - Lifetime JP4535424B2 (ja) 2001-07-06 2002-07-05 多発性骨髄腫の治療法

Country Status (13)

Country Link
US (3) US7344715B2 (enExample)
EP (1) EP1414492B1 (enExample)
JP (1) JP4535424B2 (enExample)
CN (1) CN1551783B (enExample)
AU (1) AUPR617901A0 (enExample)
CA (1) CA2461989C (enExample)
DE (1) DE60223688T2 (enExample)
DK (1) DK1414492T3 (enExample)
ES (1) ES2296952T3 (enExample)
MX (1) MXPA04000130A (enExample)
NZ (1) NZ530099A (enExample)
WO (1) WO2003004056A1 (enExample)
ZA (1) ZA200400959B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
EP1720569B1 (en) * 2004-02-27 2014-10-29 Immune System Therapeutics Ltd Target for b-cell disorders
KR100950635B1 (ko) * 2004-12-23 2010-04-01 에프. 호프만-라 로슈 아게 실험동물의 치료용 항체의 검출
GB0608444D0 (en) * 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
SG175106A1 (en) * 2009-04-07 2011-11-28 Immune System Therapeutics Ltd Method for treating immune disorders
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN102596997B (zh) 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
EP2606071B1 (en) 2010-08-17 2019-12-18 F.Hoffmann-La Roche Ag Anti-human igg1 antibody
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
IL255207B2 (en) * 2015-04-23 2023-09-01 Haemalogix Pty Ltd Myeloma antigen chimeric antigen receptors and their uses
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
CN109983027A (zh) 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
EP3890780A4 (en) * 2018-12-03 2022-08-17 HaemaLogiX Pty Ltd. METHOD OF TREATMENT
JP7817945B2 (ja) * 2020-03-27 2026-02-19 ハエマロジックス・リミテッド 組成物および方法
JP2023085151A (ja) * 2021-12-08 2023-06-20 株式会社八神製作所 体外ホウ素中性子反応を用いた幹細胞の分取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma

Also Published As

Publication number Publication date
US7344715B2 (en) 2008-03-18
DE60223688T2 (de) 2008-10-30
CN1551783A (zh) 2004-12-01
EP1414492A1 (en) 2004-05-06
CA2461989C (en) 2011-11-15
DK1414492T3 (da) 2008-04-07
ZA200400959B (en) 2005-04-26
MXPA04000130A (es) 2005-06-06
AUPR617901A0 (en) 2001-08-02
AU2006202148A1 (en) 2006-06-08
US7838041B2 (en) 2010-11-23
EP1414492B1 (en) 2007-11-21
DE60223688D1 (de) 2008-01-03
JP2005504018A (ja) 2005-02-10
WO2003004056A1 (en) 2003-01-16
US20040214761A1 (en) 2004-10-28
US20090263358A1 (en) 2009-10-22
ES2296952T3 (es) 2008-05-01
CA2461989A1 (en) 2003-01-16
NZ530099A (en) 2006-04-28
US7556803B2 (en) 2009-07-07
CN1551783B (zh) 2010-11-03
US20080199463A1 (en) 2008-08-21
EP1414492A4 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
US7556803B2 (en) Method for treating multiple myeloma
JP5219827B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
KR102695434B1 (ko) 미엘린 올리고덴드로사이트 당단백질에 결합하는 항체
US8841424B2 (en) Humanized AXL antibodies
JP5615169B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
KR20220012262A (ko) 신형 cldn18.2 결합분자
RU2746325C1 (ru) Химерные антитела для лечения заболеваний, характеризующихся отложением амилоида
KR102149565B1 (ko) in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체
TW202031687A (zh) 一種融合蛋白及其用途
TW202409087A (zh) 抗ror1抗體
JP2024028850A (ja) 抗ｐｄ－ｌ１抗体及びその製薬用途
MXPA06009759A (es) Codocito para trastornos por linfocitos b.
CN113597432B (zh) 抗EpCAM抗体及其应用
AU2002344701B2 (en) Method for treating multiple myeloma
AU2002344701A1 (en) Method for treating multiple myeloma
TW202611072A (zh) 一種bcma結合蛋白、雙特異性抗體及其製備方法和應用
HK40017293B (en) Antibody capable of binding to myelin oligodendrocyte glycoprotein
HK40017293A (en) Antibody capable of binding to myelin oligodendrocyte glycoprotein
HK1242343B (en) Compositions for inhibiting masp-2 dependent complement activation
JP2020508697A (ja) 抗ｃｘｃｒ４抗体
HK1151973A (en) Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080821

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100609

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100611

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130625

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4535424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term